Intarcia Therapeutics, Inc☆Watch⊞Compare

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Intarcia Therapeutics, Inc is one of 4291 Biotechnology companies tracked from Boston. By capital raised it ranks among the largest (ahead of 100% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst”

ABOUT US – Intarcia Life Sciences

Welcome to Intarcia Life Science , a trusted name in healthcare and wellness solutions. Our mission is to enhance lives by providing innovative, high-quality health products and services that cater to the diverse needs of individuals and families. Founded with a vision to make health and wellness accessible to everyone, Intarcia Life Science has established itself as a leader in the industry. With a focus on quality, integrity, and customer satisfaction, we deliver solutions that not only meet but exceed global standards. Our diverse portfolio includes a wide range of healthcare products, from essential medicines and vitamins to advanced wellness solutions. We are committed to research, development, and innovation, ensuring our products are safe, effective, and tailored to meet the needs of our customers. At Intarcia Life Science, we believe in empowering individuals to lead healthier lives. By bridging the gap between affordability and quality, we aim to be your reliable partner in achieving a healthier tomorrow. Join us on our journey as we strive to make the world a healthier, happier place. Our mission is to improve lives by developing, manufacturing, and delivering high-qualit

Trades publicly as ABOUT US – Intarcia Life Sciences.

As reported in public records reported — not modeled.

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Round size and date are reported; the stage label is inferred from round size (latest is Growth/Late — a round over $400M). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Raised more than 100% of sector peers (real $). Modeled value above 100% of peers (estimate).

A tighter cohort than the sector chart above — only companies at the same stage (Growth/Late) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #4 of 5.

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

1. Series A$7.0M2009-11-16
   • First recorded raise — entered as Series A.
   • 10 investors on this round.
2. Series A$9.0M2009-11-16
   • Filed alongside the prior round (same month) — likely a tranche or amendment.
   • Round roughly the size of the prior one.
   • 33 investors on this round.
3. Series A$14.5M2010-03-19
   • Came back fast: 4 mo vs the ~14 mo sector norm.
   • Round 1.6× larger than the prior — scaling up.
   • 30 investors on this round.
4. Series C$45.8M2010-08-25
   • Came back fast: 5 mo vs the ~14 mo sector norm.
   • Round 3.2× larger than the prior — scaling up.
   • 35 investors on this round.
5. Series A$5.0M2010-08-25
   • Filed alongside the prior round (same month) — likely a tranche or amendment.
   • Round 9.2× smaller than the prior — bridge or down round.
   • 8 investors on this round.
6. Series B$27.0M2010-08-25
   • Filed alongside the prior round (same month) — likely a tranche or amendment.
   • Round 5.4× larger than the prior — scaling up.
   • 32 investors on this round.
7. Series C$40.3M2010-08-25
   • Filed alongside the prior round (same month) — likely a tranche or amendment.
   • Round 1.5× larger than the prior — scaling up.
   • 34 investors on this round.
8. Series C$7.3M2012-08-07
   • Raised again after 23 mo — slower than the ~14 mo sector norm.
   • Round 5.6× smaller than the prior — bridge or down round.
   • 1 investor on this round.
9. Series D+$155.9M2012-11-14
   • Came back fast: 3 mo vs the ~14 mo sector norm.
   • Round 21.5× larger than the prior — scaling up.
   • 23 investors on this round.
10. Series C$7.9M2012-11-14
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 19.8× smaller than the prior — bridge or down round.
    • 15 investors on this round.
11. Series C$699K2012-11-14
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 11.3× smaller than the prior — bridge or down round.
    • 4 investors on this round.
12. Series D+$200.0M2014-03-27
    • Raised 16 mo later, in step with the ~14 mo sector norm.
    • Round 286.1× larger than the prior — scaling up.
    • Switched to Rule 506(b) (was Rule 06).
    • 38 investors on this round.
13. Series D+$184.4M2016-09-02
    • Raised again after 29 mo — slower than the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 28 investors on this round.
14. Series D+$390.7M2016-09-02
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.1× larger than the prior — scaling up.
    • 38 investors on this round.
15. Growth/Late$475.7M2016-09-02
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 75 investors on this round.
16. Growth/Late$524.6M2016-09-02
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 90 investors on this round.
17. Growth/Late$198.5M2019-02-26
    • Raised again after 30 mo — slower than the ~14 mo sector norm.
    • Round 2.6× smaller than the prior — bridge or down round.
    • 45 investors on this round.
18. Series C$73.1M2019-02-26
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.7× smaller than the prior — bridge or down round.
    • 30 investors on this round.

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

Intarcia Therapeutics, Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

See where Intarcia Therapeutics, Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

If you work at Intarcia Therapeutics, Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.